公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2020 | Hepatitis C virus cure rates are reduced in patients with active but not inactive hepatocellular carcinoma: A practice implication | Ogawa E.; Toyoda H.; Iio E.; Jun D.W.; Huang C.-F.; Enomoto M.; Hsu Y.-C.; Haga H.; Iwane S.; Wong G.; Lee D.H.; Tada T.; CHEN-HUA LIU ; Chuang W.-L.; Hayashi J.; Cheung R.; Yasuda S.; Tseng C.-H.; Takahashi H.; Tran S.; Yeo Y.H.; Henry L.; Barnett S.D.; Nomura H.; Nakamuta M.; Dai C.-Y.; Huang J.-F.; Yang H.-I.; Lee M.-H.; Jun M.J.; JIA-HORNG KAO ; Eguchi Y.; Ueno Y.; Tamori A.; Furusyo N.; Yu M.-L.; Tanaka Y.; Nguyen M.H.; Ahn S.B.; Azuma K.; Dohmen K.; Jeong J.Y.; Jung J.H.; Kajiwara E.; Kato M.; Kawano A.; Koyanagi T.; Ooho A.; Park S.H.; Satoh T.; Shimoda S.; Song D.S.; Takahashi K.; Yeh M.-L.; Yoon E.L.; Real-World Evidence from the Asia Liver Consortium Investigators | Clinical Infectious Diseases | 26 | 19 | |
2021 | Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort) | Hsu W.-F.; Tsai P.-C.; Chen C.-Y.; Tseng K.-C.; Lai H.-C.; Kuo H.-T.; Hung C.-H.; Tung S.-Y.; Wang J.-H.; Chen J.-J.; Lee P.-L.; Chien R.-N.; Lin C.-Y.; Yang C.-C.; Lo G.-H.; Tai C.-M.; Lin C.-W.; JIA-HORNG KAO ; CHUN-JEN LIU ; CHEN-HUA LIU ; Yan S.-L.; Bair M.-J.; Su W.-W.; Chu C.-H.; Chen C.-J.; Lo C.-C.; Cheng P.-N.; Chiu Y.-C.; Wang C.-C.; Cheng J.-S.; Tsai W.-L.; Lin H.-C.; Huang Y.-H.; Huang J.-F.; Dai C.-Y.; Chuang W.-L.; Yu M.-L.; Peng C.-Y. | Journal of Gastroenterology and Hepatology (Australia) | 7 | 10 | |
2022 | Hepatitis C virus reinfection in patients on haemodialysis after achieving sustained virologic response with antiviral treatment | CHEN-HUA LIU ; Peng, Cheng-Yuan; Kao, Wei-Yu; Yang, Sheng-Shun; Shih, Yu-Lueng; CHIH-YUAN LEE ; MENG-KUN TSAI ; Lee, Chih-Yuan; Chang, Chun-Chao; Wu, Jo-Hsuan; CHUN-JEN LIU ; TUNG-HUNG SU ; TAI-CHUNG TSENG ; PEI-JER CHEN ; JIA-HORNG KAO | Alimentary pharmacology & therapeutics | 11 | 9 | |
2022 | Hepatitis C Virus Reinfection in People With HIV in Taiwan After Achieving Sustained Virologic Response With Antiviral Treatment: The RECUR Study | CHEN-HUA LIU ; HSIN-YUN SUN ; Peng, Cheng-Yuan; SZU-MIN HSIEH ; Yang, Sheng-Shun; Kao, Wei-Yu; Shih, Yu-Lueng; Lin, Chih-Lin; CHUN-JEN LIU ; WANG-HUEI SHENG ; Lo, Yi-Chun; Liu, Wen-Chun; Wu, Jo-Hsuan; TUNG-HUNG SU ; TAI-CHUNG TSENG ; PEI-JER CHEN ; CHIEN-CHING HUNG ; JIA-HORNG KAO | Open forum infectious diseases | 9 | 7 | |
2016 | Hepatocellular carcinoma recurrence after interferon-free direct acting antiviral treatment for chronic hepatitis C virus infection: Fact or fiction? | CHEN-HUA LIU ; JIA-HORNG KAO | Translational Cancer Research | 2 | 3 | |
2020 | HEV superinfection accelerates disease progression in patients with chronic HBV infection and increases mortality in those with cirrhosis | TAI-CHUNG TSENG ; CHUN-JEN LIU ; Chang C.T; TUNG-HUNG SU ; Yang W.-T; Tsai C.-H; CHI-LING CHEN ; HUNG-CHIH YANG ; CHEN-HUA LIU ; PEI-JER CHEN ; DING-SHINN CHEN ; JIA-HORNG KAO | Journal of Hepatology | 41 | 32 | |
2008 | High hepatitis C viral load is associated with insulin resistance in patients with chronic hepatitis C | Hsu C.-S.; CHUN-JEN LIU ; CHEN-HUA LIU ; Wang C.-C.; CHI-LING CHEN ; Lai M.-Y.; PEI-JER CHEN ; JIA-HORNG KAO ; DING-SHINN CHEN | Liver International | 95 | 91 | |
2019 | High Level of Hepatitis B Core–Related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load | TAI-CHUNG TSENG ; CHUN-JEN LIU ; Hsu C.-Y; CHUN-MING HONG ; TUNG-HUNG SU ; Yang W.-T; CHI-LING CHEN ; HUNG-CHIH YANG ; Huang Y.-T; Fang-Tzu Kuo S; CHEN-HUA LIU ; PEI-JER CHEN ; DING-SHINN CHEN ; JIA-HORNG KAO | Gastroenterology | 94 | 76 | |
2012 | High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load | TAI-CHUNG TSENG ; CHUN-JEN LIU ; HUNG-CHIH YANG ; TUNG-HUNG SU ; Wang C.-C; CHI-LING CHEN ; Kuo S.F.-T; CHEN-HUA LIU ; PEI-JER CHEN ; DING-SHINN CHEN ; JIA-HORNG KAO | Gastroenterology | 430 | 381 | |
2020 | High risk of clinical relapse in patients with chronic Hepatitis B virus infection after cessation of prophylactic antiviral therapy for rituximab-containing chemotherapy | Chang W.-Y.; Chiu Y.-C; Chiu F.-W; Hsu Y.-C; TAI-CHUNG TSENG ; Cheng P.-N; Yang S.-S; CHUN-JEN LIU ; TUNG-HUNG SU ; HUNG-CHIH YANG ; CHEN-HUA LIU ; PEI-JER CHEN ; DING-SHINN CHEN ; JIA-HORNG KAO | Journal of Infectious Diseases | 5 | 5 | |
2009 | High serum adiponectin correlates with advanced liver disease in patients with chronic hepatitis B virus infection | CHUN-JEN LIU ; PEI-JER CHEN ; Lai M.-Y.; CHEN-HUA LIU ; CHI-LING CHEN ; JIA-HORNG KAO ; DING-SHINN CHEN | Hepatology International | 32 | 29 | |
2015 | Higher lifetime chance of spontaneous surface antigen loss in hepatitis B carriers with genotype C infection | TAI-CHUNG TSENG ; CHUN-JEN LIU ; CHI-LING CHEN ; Yang W.-T; HUNG-CHIH YANG ; TUNG-HUNG SU ; Wang C.-C; Kuo S.F.-T; CHEN-HUA LIU ; PEI-JER CHEN ; DING-SHINN CHEN ; JIA-HORNG KAO | Alimentary Pharmacology and Therapeutics | 48 | 43 | |
2015 | Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers | TAI-CHUNG TSENG ; CHUN-JEN LIU ; HUNG-CHIH YANG ; CHI-LING CHEN ; Yang W.-T; Tsai C.-S; Kuo S.F.-T; Verbree F.C; TUNG-HUNG SU ; Wang C.-C; CHEN-HUA LIU ; PEI-JER CHEN ; DING-SHINN CHEN ; JIA-HORNG KAO | Gut | 98 | 84 | |
2013 | IL28B genotype on HCV infection in Asia | CHEN-HUA LIU ; JIA-HORNG KAO | Current Hepatitis Reports | 3 | 0 | |
2012 | Impact of hepatitis B virus infection on metabolic profiles and modifying factors | Hsu C.-S.; CHEN-HUA LIU ; Wang C.-C.; TAI-CHUNG TSENG ; CHUN-JEN LIU ; CHI-LING CHEN ; PEI-JER CHEN ; DING-SHINN CHEN ; JIA-HORNG KAO | Journal of Viral Hepatitis | 60 | 54 | |
2022 | Impact of Sofosbuvir-Based Direct-Acting Antivirals on Renal Function in Chronic Hepatitis C Patients With Impaired Renal Function: A Large Cohort Study From the Nationwide HCV Registry Program (TACR) | Huang C.-F.; Tseng K.-C.; Cheng P.-N.; Hung C.-H.; Lo C.-C.; Peng C.-Y.; Bair M.-J.; Yeh M.-L.; Chen C.-H.; Lee P.-L.; Lin C.-Y.; Kuo H.-T.; Chen C.-T.; Yang C.-C.; Huang J.-F.; Tai C.-M.; Hu J.-T.; Lin C.-L.; Su W.-W.; Tsai W.-L.; Huang Y.-H.; Cheng C.-Y.; Lin C.-L.; Wang C.-C.; Yang S.-S.; Mo L.-R.; Chen G.-Y.; Chang C.-C.; Wang S.-J.; Huang C.-S.; Hsieh T.-Y.; Lin C.-W.; Lee T.-H.; Chong L.-W.; Huang C.-W.; Chang S.-N.; Tsai M.-C.; SHIH-JER HSU ; JIA-HORNG KAO ; CHUN-JEN LIU ; CHEN-HUA LIU ; Lin H.-C.; Lee M.-H.; Tsai P.-C.; Dai C.-Y.; Chuang W.-L.; Chen C.-Y.; Yu M.-L. | Clinical Gastroenterology and Hepatology | 14 | 12 | |
2007 | Interferon-based therapy for dialysis patients with chronic hepatitis C: Progress and challenges | CHEN-HUA LIU ; CHUN-JEN LIU ; JIA-HORNG KAO | Nephrology | 2 | 7 | |
2012 | Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy | CHEN-HUA LIU ; Liang C.-C.; CHUN-JEN LIU ; TAI-CHUNG TSENG ; Lin C.-L.; Yang S.-S.; TUNG-HUNG SU ; SHIH-JER HSU ; JOU-WEI LIN ; Chen J.-H.; PEI-JER CHEN ; DING-SHINN CHEN ; JIA-HORNG KAO | Antiviral Therapy | 40 | 39 | |
2012 | Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin | CHEN-HUA LIU ; Liang, Cheng-Chao; CHUN-JEN LIU ; TAI-CHUNG TSENG ; Lin, Chih-Lin; Yang, Sheng-Shun; TUNG-HUNG SU ; JOU-WEI LIN ; Chen, Jun-Herng; PEI-JER CHEN ; DING-SHINN CHEN ; JIA-HORNG KAO | Antiviral therapy | 21 | 22 | |
2011 | Interleukin-28B genetic variations and response to interferon-based therapy: Asian perspectives | CHEN-HUA LIU ; JIA-HORNG KAO | Journal of Gastroenterology and Hepatology (Australia) | 6 | 6 | |